Potential cardiac valve effects of dopamine agonists in hyperprolactinemia

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 3, 2010, Pages 1025-1033

  Valassi, Elena ^a   Klibanski, Anne ^a   Biller, Beverly M K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DEXFENFLURAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FENFLURAMINE; LISURIDE; PERGOLIDE; PRAMIPEXOLE; PROLACTIN; QUINAGOLIDE; ROPINIROLE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR;

ADULT; AGED; AGING; ALCOHOLISM; AORTA VALVE REGURGITATION; BLOOD PRESSURE; BODY MASS; CLINICAL PRACTICE; CONSTRICTIVE PERICARDITIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABUSE; DRUG EFFECT; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEEDING BEHAVIOR; FEMALE; GENETIC POLYMORPHISM; HEART MUSCLE FIBROSIS; HEART VALVE; HEART VALVE REGURGITATION; HUMAN; HYPERPROLACTINEMIA; HYPERTENSION; LONG TERM CARE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; NONHUMAN; PARKINSON DISEASE; PATIENT MONITORING; PLEURAL FIBROSIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; REVIEW; RISK; RISK BENEFIT ANALYSIS; SEROTONINERGIC SYSTEM; SEX DIFFERENCE; TREATMENT OUTCOME; TRICUSPID VALVE REGURGITATION; VALVULAR HEART DISEASE; CHEMICALLY INDUCED DISORDER; PATHOLOGY;

DOPAMINE AGONISTS; HEART VALVE DISEASES; HEART VALVES; HUMANS; HYPERPROLACTINEMIA;

EID: 77749234191     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2095     Document Type: Review

References (45)

1. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G 2003 Withdrawal of long-term cabergoline therapy for tumoral and non-tumoral hyperprolactinemia. N Engl J Med 349:2023-2033
2. Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G 1997 Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82:3574-3579
3. Pinero A, Marcos-Alberca P, Fortes J 2005 Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 353:1976-1977
4. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D 2004 Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 363:1179-1183
5. Antonini A, Poewe W 2007 Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 6:826-829
6. Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, Raskoff WJ, Flachsbart KD, Rakowski H, Pache JC, Burkhard PR, Lang AE 2004 Severe multivalvular heart disease: a new complication of the ergot-derivative dopamine agonists. Mov Disord 19:656-662
7. Flowers CM, Racoosin JA, Lu SL, Beitz JG 2003 The U.S. Food and Drug Administration's Registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 78:730-731
8. Ling LH, Ahlskog JE, Munger TM, Limper AH, Oh JK 1999 Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease. Mayo Clin Proc 74:371-375
9. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G 2007 Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356:39-46
10. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E 2007 Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29-38
11. Yamamoto M, Uesugi T, Nakayama T 2006 Dopamine agonists and cardiac valvulopathy in Parkinson's disease: a case-control study. Neurology 67:1225-1229
12. Yamashiro K, Komine-Kobayashi M, Hatano T, Urabe T, Mochizuki H, Hattori N, Iwama Y, Daida H, Sakai M, Nakayama T, Mizuno Y 2008 The frequency of cardiac valvular regurgitation in Parkinson's disease. Mov Disord 23:935-941
13. March 29, 2007 FDA Public Health Advisory: pergolide. http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm051192.htm
14. Andersohn F, Garbe E 2009 Cardiac and noncardiac fibrotic reactions caused by ergot- and nonergot-derived dopamine agonists. Mov Disord 24:129-133
15. Nebigil CG, Choi DS, Dierich A, Hickel P, Le Meur M, Messaddeq N, Launay JM, Maroteaux L 2000 Serotonin 2B receptor is required for heart development. Proc Natl Acad Sci USA 97:9508-9513
16. Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J 2009 Drug-induced fibrotic valvular disease. Lancet 374:577-585
17. Roth BL 2007 Drugs and valvular heart disease. N Engl J Med 356:6-9
18. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL 2000 Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102:2836-2841
19. Serratrice J, Disdier P, Habib G, Viallet F, Weiller PJ 2002 Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 10:334-336
20. Rinne UK 1981 Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease. Lancet 1:44
21. Kinnunen E, Viljanen A 1988 Pleuropulmonary involvement during bromocriptine treatment. Chest 94:1034-1036
22. McElvaney NG, Wilcox PG, Churg A, Fleetham JA 1988 Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease. Arch Intern Med 148:2231-2236
23. Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, Lehman B, Benjamin EJ 1999 Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 83:897-902
24. Choong CY, Abascal VM, Weyman J, Levine RA, Gentile F, Thomas JD, Weyman AE 1989 Prevalence of valvular regurgitation by Doppler echocardiography in patients with structurally normal hearts by two-dimensional echocardiography. Am Heart J 117:636-642
25. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, Nihoyannopoulos P, Otto CM, Quinones MA, Rakowski H, Stewart WJ, Waggoner A, Weissman NJ; American Society of Echocardiography 2003 Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16:777-802
26. Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M, Guerra E, Pivonello R, Lerro G, Lombardi G 2008 Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 93:3777-3784
27. Oeda T, Masaki M, Yamamoto K, Mizuta E, Kitagawa N, Isono T, Taniguchi S, Doi K, Yaku H, Yutani C, Kawamura T, Kuno S, Sawada H 2009 High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease. J Neural Transm 116:171-178
28. Bogazzi F, Buralli S, Manetti L, Raffaelli V, Cigni T, Lombardi M, Boresi F, Taddei S, Salvetti A, Martino E 2008 Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinemia. Int J Clin Pract 62:1864-1869
29. Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, Kahtani N, Beauregard H, Aris-Jilwan N, Houde G, Serri O 2009 Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 12:153-157
30. Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA 2009 Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf) 70:104-108
31. Nachtigall L, Valassi E, Lo J, Mc Carty D, Passeri J, Utz A, Biller BMK, Miller KK, Klibanski A 17 April 2009 Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin Endocrinol (Oxf) doi: 10.1111/j.1365-2265.2009.03608.x
32. Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ, Pereira AM 2008 Aortic valve calcification and mild tricuspid regurgitation, but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 93:3348-3356
33. Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL 2008 Low dose of cabergoline for hyperprolactinemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 159:R11-R14
34. Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D, Pierard L, Beckers A 2008 Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 159:1-5
35. Devin JK, Lakhani VT, Byrd 3rd BF, Blevins Jr LS 2008 Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr Pract 14:672-677
36. Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K 2008 Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 93:4721-4727
37. Kars M, Pereira AM, Bax JJ, Romijn JA 2008 Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol 159:363-367
38. Malhotra AK, Murphy Jr GM, Kennedy JL 2004 Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161:780-796
39. Lin Z, Walther D, Yu XY, Drgon T, Uhl GR 2004 The human serotonin receptor 2B: coding region polymorphisms and association with vulnerability to illegal drug abuse. Pharmacogenetics 14:805-811
40. Fox ER, Wilson RS, Penman AD, King JJ, Towery JG, Butler KR, McMullan MR, Skelton TN, Mosley TH, Taylor HA 2007 Epidemiology of pure valvular regurgitation in the large middle-aged African American cohort of the Atherosclerosis Risk in Communities study. Am Heart J 154:1229-1234
41. Bogazzi F, Manetti L, Raffaelli V, Lombardi M, Rossi G, Martino E 2008 Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J Endocrinol Invest 31:1119-1123
42. Molitch ME 2008 The cabergoline-resistant prolactinoma patient: new challenges. J Clin Endocrinol Metab 93:4643-4645
43. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF 1994 A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 331:904-909
44. Klibanski A 2009 Dopamine agonist therapy in prolactinomas: when can treatment be discontinued? J Clin Endocrinol Metab 94:2247-2249
45. Kharlip J, Salvatori R, Yenokyan G, Wand GS 2009 Recurrence of hyperprolactinemia following withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 94:2428-2436